Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

Body composition and quality of life (QOL) with lenvatinib + everolimus (len + eve) versus cabozantinib (cabo) in metastatic clear cell renal cell carcinoma (ccRCC) after PD-1 inhibitor progression: Results from the randomized phase II LenCabo trial.

Julia Moura, Jad Chahoud, William Paul Skelton et al. Jun 01, 2026 pp. 4538-4538 10.1200/jco.2026.44.16_suppl.4538

4538 Background: The LenCabo trial (NCT05012371) was the first randomized head-to-head comparison of contemporary second-l...

Efficacy and toxicity of CDK4/6 inhibitors in early and metastatic HR+/HER2– breast cancer.

Ravneet Kaur Dhanoa, Sumin Thapa, Pragnan Kancharla et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13047

e13047 Background: Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors improve outcomes in metastatic hormone receptor-positiv...

Effects of a multimodal TCR/BCR repertoire foundation model on blood RNA-seq–based prediction of severe adverse event risk and rheumatoid arthritis.

Anatoly Bobe, Dmitrii Fastovets, Armen Harutyunian et al. Jun 01, 2026 pp. 2570-2570 10.1200/jco.2026.44.16_suppl.2570

2570 Background: Severe immune-related adverse events (irAEs) limit the use of immune checkpoint inhibitors (ICIs). Clinic...

Cardiac substructure dose signatures as predictors of late cardiovascular events in childhood cancer survivors.

Hrushikesh Reddy Pamreddy, Panah Tushar Parab, Sharanya Tripathi et al. Jun 01, 2026 pp. 12123-12123 10.1200/jco.2026.44.16_suppl.12123

12123 Background: Radiation-associated cardiovascular disease (CVD) remains a major late toxicity in childhood cancer surv...

Interpretable AI-driven pan-cancer pre-screening of actionable gene fusions from H&E slides: A prototype-guided mixture-of-experts framework to prioritize patients for RNA/DNA sequencing.

Zheyi Ji, Lingjie Fan, Zhangwen Li et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15011

e15011 Background: Actionable gene fusions such as ALK, ROS1, and...

Tislelizumab, bevacizumab, and chemotherapy as second-line therapy in PD-L1-positive, RAS-mutant metastatic colorectal cancer: A single-arm, phase II clinical trial.

Luoyan Ai, Xiaojing Xu Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15540

e15540 Background: The therapeutic options for RAS-mutant metastatic colorectal cancer (mCRC) post first-line therapy are...

Cardiac complications as a major driver of ICU utilization in hospitalized cancer patients: A National Inpatient Sample analysis, 2018–2022.

Simranjit Shergill, Bryce Krason, Daniel Thomas Jones et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23167

e23167 Background: ICU-level escalation in hospitalized cancer patients is commonly attributed to sepsis or respiratory fa...

Endocrine therapy non-adherence and recurrence risk in patients with breast cancer and major depressive disorder.

Maya Aboumrad, Corinne Joshu, John Jackson et al. Jun 01, 2026 pp. 10595-10595 10.1200/jco.2026.44.16_suppl.10595

10595 Background: We evaluated whether non-adherence to oral endocrine therapy explains the increased hazard of recurrence...

Global incidence, mortality, and projections of early-onset upper gastrointestinal cancers.

Manas Pustake, Deevyashali Parekh, Nicholas James Hornstein et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16339

e16339 Background: Cancers of the upper gastrointestinal tract remain major contributors to morbidity and mortality worldw...

An open-label, parallel-cohort, multicenter clinical study of rezvilutamide in combination with androgen deprivation therapy (ADT) with or without docetaxel in the neoadjuvant treatment of oligometastatic prostate cancer.

Qi Lin, Xin-xu Zhu, Wei Chen et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps5148

TPS5148 Background: Oligometastatic hormone-sensitive prostate cancer (omHSPC), defined by ≤5 metastases, represents a dis...

Understanding barriers to the clinical breast exam in Telangana, India: A survey study of participants and non-participants in underserved rural and urban areas.

Nina Tamirisa, Manisha Koppala, Vedha Penmetcha et al. Jun 01, 2026 pp. 1593-1593 10.1200/jco.2026.44.16_suppl.1593

1593 Background: In low-resource settings where mammography is not feasible, Clinical Breast Examination (CBE) performed b...

Burden of heart failure–related mortality among U.S. adults with leukemia (1999-2023).

Harshitha Bandaru Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e18623

e18623 Background: Cardiovascular disease is the leading non-cancer cause of death among leukemia survivors, with heart fa...

Radium-223 without androgen deprivation therapy (ADT) in patients (Pts) with biochemically recurrent prostate cancer (BCR) and PET findings in the bones.

Melissa Lauren Abel, Fatima Karzai, Philip M. Arlen et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e17107

e17107 Background: BCR pts have a rising PSA after definitive surgery or radiation, but negative CT/Tc-99m bone scans. Whi...

Machine learning approach to identify country-specific drivers of global cancer outcomes.

Erin Feliciano, Milit S. Patel, C.S. Pramesh et al. Jun 01, 2026 pp. 1596-1596 10.1200/jco.2026.44.16_suppl.1596

1596 Background: Global disparities in access to cancer diagnostics and care drive substantial variation in cancer outcome...

The Remote Emotional Support and Symptom Self-Management Intervention (REMI): A pilot study.

Hannah Kwiecinski, Saeed Abdullah, Yael Schenker et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e24070

e24070 Background: Symptom burdens related to advanced cancer remain high. The Remote Emotional Support and Symptom Self-M...

Risk-adapted step-up local therapy for malignant portal vein tumor thrombus from hepatic metastases: A real-world study of microwave ablation with and without iodine-125 seed implantation.

Hoang Tran Pham, Li Chun, Weidong Bao et al. Jun 01, 2026 pp. 4235-4235 10.1200/jco.2026.44.16_suppl.4235

4235 Background: Malignant portal vein tumor thrombus (PVTT) arising from hepatic metastases is associated with poor progn...

Combined therapy using gemcitabine and cisplatin chemotherapy, lenvatinib, and adebrelimab for patients with advanced and unresectable intrahepatic cholangiocarcinoma: A prospective, single-arm, phase II trial.

Mengya Zang, Weiwei Peng, Xiaobing Yang et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16190

e16190 Background: The prognosis of advanced intrahepatic cholangiocarcinoma (ICC) remains unsatisfactory with current gem...

A phase II trial of a novel induction regimen: Polymeric micellar paclitaxel plus cisplatin for locally advanced head and neck squamous cell carcinoma.

Wenchao Zhang, Zhenyu Wang, Shaoyan Wen et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e18067

e18067 Background: Induction chemotherapy with the TPF regimen is recommended by international guidelines for locally adva...

Intralesional PD-1 blockade for oral cancer prevention: First-in-class phase 1 trial.

Moran Amit, Robert Saddawi-Konefka, Shorook Naara et al. Jun 01, 2026 pp. 10517-10517 10.1200/jco.2026.44.16_suppl.10517

10517 Background: Oral premalignant lesions affect 5% of the global population with transformation rates of 1-8% in mild-m...

Thematic game intervention as a novel psychosocial support to reduce sedation needs and anxiety in pediatric neuro-oncology patients during radiotherapy: A prospective cohort study (2020–2025).

Fuqiang Zhang, Xing Zhang, Mingyao Lai et al. Jun 01, 2026 pp. 10011-10011 10.1200/jco.2026.44.16_suppl.10011

10011 Background: Pediatric neuro-oncology patients undergoing radiotherapy frequently require sedation/anesthesia due to...

Cancer-related fatigue research at the National Institutes of Health (NIH) from 2015-2024.

Rachel Altshuler, Vanessa A. White, Catherine Schweppe et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e24059

e24059 Background: Cancer-related fatigue (CRF) is a highly prevalent symptom in cancer patients, significantly impacting...

Predicting pathological complete response based on multi-time point <sup>18</sup> F-FAPI PET/CT in locally advanced rectal cancer.

Minyi He, Huiting Yang, Yunxing Shi et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15649

e15649 Background: Accurate prediction of pathological complete response (pCR) following neoadjuvant short-course radiothe...

Genetic correlation and causal associations between metabolic traits and lung cancer risk.

Knightess Oyibo, Michael Zhong, Clement Adebamowo et al. Jun 01, 2026 pp. 10599-10599 10.1200/jco.2026.44.16_suppl.10599

10599 Background: Lung cancer is the leading cause of cancer-related mortality worldwide. We evaluated whether association...

Tislelizumab combined with bevacizumab and trifluridine/tipiracil as third-line or later therapy for metastatic colorectal cancer (mCRC) : A real-world study.

Luping Lin, Sha Huang, Jianwei Yang Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15554

e15554 Background: Microsatellite stable (MSS) patients (pts) account for 95% of metastatic colorectal cancer (mCRC) cases...

Oncologic impact of prophylactic oophorectomy in colorectal cancer surgery: A systematic review and meta-analysis.

Caio Pluvier Duarte Costa, Ana Paula Valério-Alves, Pedro Neves Borges et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15536

e15536 Background: The evidence supporting routine prophylactic oophorectomy (PO) during colorectal cancer surgery remains...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page